Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease

Claus Aalykke; Michael Dam Jensen; Jan Fallingborg; Tine Jess; Ebbe Langholz; Søren Meisner; Nynne Nyboe Andersen; Lene Buhl Riis; Ole Østergaard Thomsen; Anders Tøttrup

Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease

Claus Aalykke, Michael Dam Jensen, Jan Fallingborg, Tine Jess, Ebbe Langholz, Søren Meisner, Nynne Nyboe Andersen, Lene Buhl Riis, Ole Østergaard Thomsen, Anders Tøttrup

2 Citations (Scopus)

Abstract

The risk of colorectal cancer (CRC) and dysplasia in patients with inflammatory bowel disease (IBD) has been highly debated as risk estimates from different studies vary greatly. The present national Danish guideline on colonoscopy surveillance for dysplasia and colorectal cancer in patients with IBD is based on a thorough review of existing literature with particular focus on recent studies from Denmark revealing a lower risk of CRC than previously assumed. The overall risk of CRC in the Danish IBD population does not appear to be different from that of the background population; however, in some subgroups of patients the risk is increased. These subgroups of patients, who should be offered colonoscopy surveillance, include patients with ulcerative colitis having extensive disease and a long disease duration (10-13 years); early age at onset (less than 19 years of age) of ulcerative colitis; and patients with ulcerative colitis as well as Crohn's disease with a concomitant diagnosis of primary sclerosing cholangitis. A colonoscopy surveillance program is recommended in these subgroups with intervals ranging from every 3-6 months to every 5 years, using chromoendoscopy with targeted biopsies of the lesion and adjacent mucosa, instead of conventional colonoscopy with random biopsies. Preferably, the colonoscopy should be performed during clinical remission. If a lesion is detected the endoscopical resectability together with the pathology of the lesion and the adjacent mucosa determine how the lesion should be treated.

Original language	English
Journal	Danish Medical Journal
Volume	62
Issue number	1
Pages (from-to)	B4995
ISSN	1603-9629
Publication status	Published - 1 Jan 2015
Externally published	Yes

Keywords

Age of Onset
Biopsy/methods
Colitis, Ulcerative/complications
Colon/pathology
Colonoscopy/methods
Colorectal Neoplasms/diagnosis
Crohn Disease/complications
Denmark
Female
Humans
Hyperplasia/diagnosis
Inflammatory Bowel Diseases/complications
Intestinal Mucosa/pathology
Male
Population Surveillance/methods
Time Factors

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{70ed205234df43ababfc833862da2776,

title = "Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease",

abstract = "The risk of colorectal cancer (CRC) and dysplasia in patients with inflammatory bowel disease (IBD) has been highly debated as risk estimates from different studies vary greatly. The present national Danish guideline on colonoscopy surveillance for dysplasia and colorectal cancer in patients with IBD is based on a thorough review of existing literature with particular focus on recent studies from Denmark revealing a lower risk of CRC than previously assumed. The overall risk of CRC in the Danish IBD population does not appear to be different from that of the background population; however, in some subgroups of patients the risk is increased. These subgroups of patients, who should be offered colonoscopy surveillance, include patients with ulcerative colitis having extensive disease and a long disease duration (10-13 years); early age at onset (less than 19 years of age) of ulcerative colitis; and patients with ulcerative colitis as well as Crohn's disease with a concomitant diagnosis of primary sclerosing cholangitis. A colonoscopy surveillance program is recommended in these subgroups with intervals ranging from every 3-6 months to every 5 years, using chromoendoscopy with targeted biopsies of the lesion and adjacent mucosa, instead of conventional colonoscopy with random biopsies. Preferably, the colonoscopy should be performed during clinical remission. If a lesion is detected the endoscopical resectability together with the pathology of the lesion and the adjacent mucosa determine how the lesion should be treated.",

keywords = "Age of Onset, Biopsy/methods, Colitis, Ulcerative/complications, Colon/pathology, Colonoscopy/methods, Colorectal Neoplasms/diagnosis, Crohn Disease/complications, Denmark, Female, Humans, Hyperplasia/diagnosis, Inflammatory Bowel Diseases/complications, Intestinal Mucosa/pathology, Male, Population Surveillance/methods, Time Factors",

author = "Claus Aalykke and Jensen, {Michael Dam} and Jan Fallingborg and Tine Jess and Ebbe Langholz and S{\o}ren Meisner and Andersen, {Nynne Nyboe} and Riis, {Lene Buhl} and Thomsen, {Ole {\O}stergaard} and Anders T{\o}ttrup",

year = "2015",

month = jan,

day = "1",

language = "English",

volume = "62",

pages = "B4995",

journal = "Danish Medical Journal",

issn = "2245-1919",

publisher = "Almindelige Danske Laegeforening",

number = "1",

}

TY - JOUR

T1 - Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease

AU - Aalykke, Claus

AU - Jensen, Michael Dam

AU - Fallingborg, Jan

AU - Jess, Tine

AU - Langholz, Ebbe

AU - Meisner, Søren

AU - Andersen, Nynne Nyboe

AU - Riis, Lene Buhl

AU - Thomsen, Ole Østergaard

AU - Tøttrup, Anders

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The risk of colorectal cancer (CRC) and dysplasia in patients with inflammatory bowel disease (IBD) has been highly debated as risk estimates from different studies vary greatly. The present national Danish guideline on colonoscopy surveillance for dysplasia and colorectal cancer in patients with IBD is based on a thorough review of existing literature with particular focus on recent studies from Denmark revealing a lower risk of CRC than previously assumed. The overall risk of CRC in the Danish IBD population does not appear to be different from that of the background population; however, in some subgroups of patients the risk is increased. These subgroups of patients, who should be offered colonoscopy surveillance, include patients with ulcerative colitis having extensive disease and a long disease duration (10-13 years); early age at onset (less than 19 years of age) of ulcerative colitis; and patients with ulcerative colitis as well as Crohn's disease with a concomitant diagnosis of primary sclerosing cholangitis. A colonoscopy surveillance program is recommended in these subgroups with intervals ranging from every 3-6 months to every 5 years, using chromoendoscopy with targeted biopsies of the lesion and adjacent mucosa, instead of conventional colonoscopy with random biopsies. Preferably, the colonoscopy should be performed during clinical remission. If a lesion is detected the endoscopical resectability together with the pathology of the lesion and the adjacent mucosa determine how the lesion should be treated.

AB - The risk of colorectal cancer (CRC) and dysplasia in patients with inflammatory bowel disease (IBD) has been highly debated as risk estimates from different studies vary greatly. The present national Danish guideline on colonoscopy surveillance for dysplasia and colorectal cancer in patients with IBD is based on a thorough review of existing literature with particular focus on recent studies from Denmark revealing a lower risk of CRC than previously assumed. The overall risk of CRC in the Danish IBD population does not appear to be different from that of the background population; however, in some subgroups of patients the risk is increased. These subgroups of patients, who should be offered colonoscopy surveillance, include patients with ulcerative colitis having extensive disease and a long disease duration (10-13 years); early age at onset (less than 19 years of age) of ulcerative colitis; and patients with ulcerative colitis as well as Crohn's disease with a concomitant diagnosis of primary sclerosing cholangitis. A colonoscopy surveillance program is recommended in these subgroups with intervals ranging from every 3-6 months to every 5 years, using chromoendoscopy with targeted biopsies of the lesion and adjacent mucosa, instead of conventional colonoscopy with random biopsies. Preferably, the colonoscopy should be performed during clinical remission. If a lesion is detected the endoscopical resectability together with the pathology of the lesion and the adjacent mucosa determine how the lesion should be treated.

KW - Age of Onset

KW - Biopsy/methods

KW - Colitis, Ulcerative/complications

KW - Colon/pathology

KW - Colonoscopy/methods

KW - Colorectal Neoplasms/diagnosis

KW - Crohn Disease/complications

KW - Denmark

KW - Female

KW - Humans

KW - Hyperplasia/diagnosis

KW - Inflammatory Bowel Diseases/complications

KW - Intestinal Mucosa/pathology

KW - Male

KW - Population Surveillance/methods

KW - Time Factors

M3 - Journal article

C2 - 25557336

SN - 2245-1919

VL - 62

SP - B4995

JO - Danish Medical Journal

JF - Danish Medical Journal

IS - 1

ER -

Colonoscopy surveillance for dysplasia and colorectal cancer in patients with inflammatory bowel disease

Abstract

Keywords

UN SDGs

Fingerprint

Cite this